| Identification | Back Directory | [Name]
leminoprazole | [CAS]
104340-86-5 | [Synonyms]
NC-1300O-3
NC-1300-O-3
2-[[2-(Methylisobutylamino)benzyl]sulfinyl]-1H-benzimidazole
N-Methyl-N-(2-methylpropyl)-2-[[(1H-benzimidazol-2-yl)sulfinyl]methyl]benzenamine | [Molecular Formula]
C19H23N3OS | [MDL Number]
MFCD00866867 | [MOL File]
104340-86-5.mol | [Molecular Weight]
341.47 |
| Hazard Information | Back Directory | [Uses]
Leminoprazole (NC 1300O3) is an inhibitor for acid pump, H+ K+-ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active[1][2][3]. | [in vivo]
Leminoprazole (10-90 mg/kg, po, single dose) promotes the synthesis of gastric mucus, inhibits gastric acid secretion in Donryu rats model[3]. | Animal Model: | Donyru rats model[3] | | Dosage: | 10-90 mg/kg | | Administration: | p.o., single dose | | Result: | Increased levels of glucosamine, decreased acid secretion. |
| [References]
[1] Masuda M, et al., [Studies on the inhibitory action of leminoprazole against rabbit gastric H+,K(+)-ATPase]. Nihon Yakurigaku Zasshi. 1994 Oct;104(4):325-35. Japanese. DOI:10.1254/fpj.104.325
[2] Saito E, et al., Inhibitory effect of leminoprazole on acid secretion in parietal cells isolated from guinea pig gastric mucosa. Jpn J Pharmacol. 1995 May;68(1):19-23. DOI:10.1254/jjp.68.19
[3] Takahashi S, et al., Mechanism by which orally administered leminoprazole stimulates mucus synthesis in rats. Pharmacology. 1998 Jul;57(1):47-56. DOI:10.1159/000028225 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|